D'Angelillo Rolando Maria, Caffo Orazio, Borsellino Nicolò, Cardone Giampiero, Colloca Giuseppe Ferdinando, Conti Giario Natale, Del Re Marzia, Fanti Stefano, Jereczek-Fossa Barbara Alicja, Lapini Alberto, Pappagallo Giovanni Luigi, Prayer Galetti Tommaso, Bracarda Sergio
Radiation Oncology, Department of Biomedicine and Prevention University of Rome "Tor Vergata", Rome, Italy.
Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy.
Clin Genitourin Cancer. 2025 Feb;23(1):102292. doi: 10.1016/j.clgc.2024.102292. Epub 2024 Dec 16.
The recent evidences provided in metastatic hormone sensitive prostate cancer (nmHSPC) and in nonmetastatic castration resistant (nmCRPC) introduced the possibility to adopt Androgen Receptor Signaling inhibitor (ARSi) alone (both settings) or with chemotherapy (in mHSPC). In daily clinical practice there are some opening questions regarding the inclusion of next generation imaging, mainly PSMA-PET, how integrate local treatment as radiotherapy, how to select patients or drugs in a multiple-choice scenario, and how to manage patients with comorbidities and polypharmacy. These issues led the Italian Society for Uro-Oncology (SIUrO) to develop a consensus project involving all of the most important Italian scientific societies engaged in the multidisciplinary and multiprofessional management of the disease. This paper describes the items and statements approved, with the aim to support clinicians in managing metastatic hormone sensitive and nonmetastatic castration resistant prostate cancer patients.
转移性激素敏感性前列腺癌（nmHSPC）和非转移性去势抵抗性前列腺癌（nmCRPC）的最新证据表明，有可能单独采用雄激素受体信号抑制剂（ARSi）（在这两种情况下）或与化疗联合使用（在mHSPC中）。在日常临床实践中，关于纳入下一代成像（主要是PSMA-PET）、如何整合局部治疗（如放疗）、如何在多种选择的情况下选择患者或药物以及如何管理合并症和多重用药患者等方面存在一些开放性问题。这些问题促使意大利泌尿肿瘤学会（SIUrO）开展了一个共识项目，该项目涉及参与该疾病多学科和多专业管理的所有最重要的意大利科学学会。本文描述了已批准的项目和声明，旨在支持临床医生管理转移性激素敏感性和非转移性去势抵抗性前列腺癌患者。
